SEC Form 4/A · accession 0001053369-15-000019
ELITE PHARMACEUTICALS INC /NV/ · ELTP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Ashok G Nigalaye
Officer — Chief Scientific Officer · Director · 10% Owner
Period of report
Apr 25, 2013
Accepted (ET)
Apr 27, 2015 · 2:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001053369
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F1 | Apr 29, 2013 | D | 140,000 | $0.08 | D | 30,366,536 | I | By Epic Investments, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Ashok G. Nigalaye is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI") (which is controlled by EP), which owns securities convertible into or exercisable for in excess of 10% of the outstanding shares of common stock of the issuer, and also serves as a director of the issuer.
- F2This transaction was originally reported as 130,000 when the correct number was actually 140,000.
- F3Of the 30,366,536 shares of common stock, 22,767,183 shares of common stock are owned indirectly through EI and 7,599,356 shares are owned directly by the reporting person.